European Journal of Biomedical and Pharmaceutical Sciences

A REVIEW ON PYRIMIDINES AND PROTEIN KINASE INHIBITORS AS ANTICANCER AGENTS

Sanober Ansari and Sathish Kumar Mittapalli*

ABSTRACT

The anticancer potential of fused pyrimidine scaffolds has been evidenced number of research articles, patent literature and different enzymes/receptors/targets involved targeting as anticancer agents. A new series of pyrimidine and fused pyrimidines derivatives reported as major focused area at present for researchers all over the globe. Cellular kinases are important role in cell proliferation & differentiation of cell and human genome encodes huge number of protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues and many of these kinases are associated with human cancer initiation and progression which is second most targeted groups for ligands, after the G-protein-coupled receptors. The review, provide an in depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors the information provider in development of novel agents in relation to oncology and to meet the challenges for kinase-targeted cancer therapies.

Keywords: Pyrimidine, protein kinase, anticancer, binding site.